Roquefort Therapeutics (LON:ROQ) Trading Down 14.9% – Should You Sell?

Posted by Carolyn Dwyer on Feb 6th, 2025

Roquefort Therapeutics plc (LON:ROQ – Get Free Report) shares dropped 14.9% during trading on Tuesday . The company traded as low as GBX 3.18 ($0.04) and last traded at GBX 3.32 ($0.04). Approximately 1,854,913 shares were traded during trading, an increase of 41% from the average daily volume of 1,314,913 shares. The stock had previously closed at GBX 3.90 ($0.05).

Roquefort Therapeutics Trading Up 19.1 %

The business has a 50 day simple moving average of GBX 4 and a 200-day simple moving average of GBX 3.99. The company has a current ratio of 0.79, a quick ratio of 3.07 and a debt-to-equity ratio of 12.37. The stock has a market capitalization of £3.54 million, a price-to-earnings ratio of -274.00 and a beta of 0.05.

Insiders Place Their Bets

In related news, insider Stephen Paul West acquired 400,000 shares of Roquefort Therapeutics stock in a transaction that occurred on Tuesday, February 4th. The stock was acquired at an average price of GBX 3 ($0.04) per share, for a total transaction of £12,000 ($15,001.88). 60.40% of the stock is owned by company insiders.

About Roquefort Therapeutics

(Get Free Report)

Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.